AR070886A1 - NEW DROSPIRENONA REGIME / 17 BETA-ESTRADIOL, COMBINED PHARMACEUTICAL PRODUCT AND ELEMENTS SET (KIT) FOR APPLICATION - Google Patents
NEW DROSPIRENONA REGIME / 17 BETA-ESTRADIOL, COMBINED PHARMACEUTICAL PRODUCT AND ELEMENTS SET (KIT) FOR APPLICATIONInfo
- Publication number
- AR070886A1 AR070886A1 ARP090100902A AR070886A1 AR 070886 A1 AR070886 A1 AR 070886A1 AR P090100902 A ARP090100902 A AR P090100902A AR 070886 A1 AR070886 A1 AR 070886A1
- Authority
- AR
- Argentina
- Prior art keywords
- phase
- beta
- estradiol
- pharmaceutical product
- dosage unit
- Prior art date
Links
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 title abstract 8
- METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 title abstract 5
- 229960004845 drospirenone Drugs 0.000 title abstract 5
- 229960005309 estradiol Drugs 0.000 title abstract 4
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract 3
- 229940127557 pharmaceutical product Drugs 0.000 title abstract 3
- METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 abstract 4
- 239000006187 pill Substances 0.000 abstract 3
- 239000000902 placebo Substances 0.000 abstract 2
- 229940068196 placebo Drugs 0.000 abstract 2
- ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicacion 1: Un producto farmacéutico combinado trifásico con 24 unidades de dosificacion diarias consecutivas en sus tres fases, caracterizado porque comprende en cada fase del producto trifásico 6 a 10 unidades de dosificacion diarias en donde la cantidad de drospirenona disminuye de 3,0 mg de drospirenona en cada unidad de dosificacion diaria en la primera fase a 1,5 mg de drospirenona en cada unidad de dosificacion diaria en la tercera fase y en donde la cantidad de drospirenona en cada unidad de dosificacion diaria de la segunda fase es mayor que 1,5 mg y menor que 3,0 mg y en donde la cantidad de 17beta-estradiol aumenta de 1,0 mg en cada unidad de dosificacion en la primera fase hasta una cantidad de 2,0 mg de 17beta-estradiol en la tercera fase y en donde la cantidad de 17beta-estradiol en cada unidad de dosificacion diaria de la segunda fase es mayor que 1,0 mg y menor que 2,0 mg y 4 píldoras de placebo sin ingrediente activo u otras indicaciones para mostrar que la administracion diaria de las 24 unidades de dosificacion debe ser seguida por 4 días sin píldoras o con píldoras de placebo. Reivindicacion 6: El producto farmacéutico combinado de acuerdo con la reivindicacion 1, caracterizado porque hay entre 0,1 y 10 mg de 5-metil-(6S)-tetrahidrofolato en cada unidad de dosificacion.Claim 1: A three-phase combined pharmaceutical product with 24 consecutive daily dosage units in its three phases, characterized in that it comprises in each phase of the three-phase product 6 to 10 daily dosage units wherein the amount of drospirenone decreases from 3.0 mg drospirenone in each daily dosage unit in the first phase to 1.5 mg of drospirenone in each daily dosage unit in the third phase and where the amount of drospirenone in each daily dosage unit of the second phase is greater than 1.5 mg and less than 3.0 mg and where the amount of 17 beta-estradiol increases from 1.0 mg in each dosage unit in the first phase to an amount of 2.0 mg of 17 beta-estradiol in the third phase and in where the amount of 17 beta-estradiol in each daily dosage unit of the second phase is greater than 1.0 mg and less than 2.0 mg and 4 placebo pills without active ingredient or other indications to show that the a Daily administration of the 24 dosage units should be followed for 4 days without pills or with placebo pills. Claim 6: The combined pharmaceutical product according to claim 1, characterized in that there are between 0.1 and 10 mg of 5-methyl- (6S) -tetrahydrofolate in each dosage unit.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3620708P | 2008-03-13 | 2008-03-13 | |
| US4039708P | 2008-03-28 | 2008-03-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070886A1 true AR070886A1 (en) | 2010-05-12 |
Family
ID=41665344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100902 AR070886A1 (en) | 2008-03-13 | 2009-03-13 | NEW DROSPIRENONA REGIME / 17 BETA-ESTRADIOL, COMBINED PHARMACEUTICAL PRODUCT AND ELEMENTS SET (KIT) FOR APPLICATION |
Country Status (4)
| Country | Link |
|---|---|
| AR (1) | AR070886A1 (en) |
| CL (1) | CL2009000608A1 (en) |
| PE (1) | PE20091695A1 (en) |
| UY (1) | UY31709A (en) |
-
2009
- 2009-03-13 UY UY0001031709A patent/UY31709A/en not_active Application Discontinuation
- 2009-03-13 AR ARP090100902 patent/AR070886A1/en unknown
- 2009-03-13 PE PE2009000375A patent/PE20091695A1/en not_active Application Discontinuation
- 2009-03-13 CL CL2009000608A patent/CL2009000608A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UY31709A (en) | 2009-11-10 |
| CL2009000608A1 (en) | 2010-03-26 |
| PE20091695A1 (en) | 2009-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2009003231A (en) | USE OF ESTRADIOL VALERATE OR 17B-ESTRADIOL IN COMBINATION WITH DIENOGEST IN AN ORAL THERAPY TO MAINTAIN AND / OR IMPLEMENT FEMALE FREE | |
| NO20081038L (en) | Pharmaceutical formulations / compositions of guanfacine suitable for daily single dosage form administration | |
| EP4512394A3 (en) | Dosage forms and use thereof | |
| MX2009007742A (en) | Multi-phasic pharmaceutical formulations of poorly water-soluble drugs for reduced fed/fasted variability and improved oral bioavailability. | |
| ATE509616T1 (en) | TOPICAL PHARMACEUTICAL AND/OR COSMETIC DOSAGE SYSTEMS | |
| CO6210803A2 (en) | FORMULATIONS LIQUID FORMERS OF DERMIC FILM FOR THE RELEASE OF PHARMACO TO THE SKIN | |
| WO2008142572A3 (en) | Controlled release tablet formulation containing magnesium aluminometasilicate | |
| WO2010127205A3 (en) | Fixed dose drug combination formulations | |
| AR025938A1 (en) | NEW PHARMACEUTICAL COMPOSITIONS. | |
| WO2010098627A3 (en) | Pharmaceutical preparation | |
| AR065971A1 (en) | NEW DROSPERINONA / 17BETA-ESTRADIOL REGIME, COMBINED PHARMACEUTICAL PRODUCT AND SET OF ELEMENTS (KIT) FOR APPLICATION | |
| MX391191B (en) | EXTENDED-RELEASE COMPOSITIONS OF ONAPRISTONE AND METHODS. | |
| AR075866A1 (en) | A DOSE OF AVE5026 FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE RENAL DETERIORATION. USE. PHARMACEUTICAL COMPOSITION | |
| ZA202003904B (en) | Drug delivery system | |
| AR070886A1 (en) | NEW DROSPIRENONA REGIME / 17 BETA-ESTRADIOL, COMBINED PHARMACEUTICAL PRODUCT AND ELEMENTS SET (KIT) FOR APPLICATION | |
| AR072246A1 (en) | DROSPIRENONA REGIME / 17 BETA -ESTRADIOL, COMBINED PHARMACEUTICAL PRODUCT AND ELEMENTS ASSEMBLY (KIT) FOR APPLICATION | |
| BR112012020415A2 (en) | pharmaceutical composition for the prevention or treatment of osteoarthritis | |
| CL2012003685A1 (en) | Pharmaceutical kit comprising one or more packaging units comprising 21 to 28 daily active dosing units in which each comprises at least 2 mg of drosperidone, without spoiling us; use of the kit and a pharmaceutical composition comprising drosperidone to prepare a useful medication as a contraceptive. | |
| EA201290378A1 (en) | COMPOSITIONS CONTAINING NESTEROIDIC ANTI-INFLAMMATORY MEDICINES | |
| MX2018015759A (en) | Vortioxetine dosing regimes for fast onset of antidepressant effect. | |
| AR086252A1 (en) | TOPICAL FORMULATION THAT INCLUDES BECLOMETASONE DIPROPIONATE AS ACTIVE INGREDIENT | |
| BR112015010650A2 (en) | improved levonorgestrel-containing composition only for optimized oral contraception with defined levonorgestrel content, dosage regimen and pharmaceutical preparation | |
| EP4389147A3 (en) | Therapeutic formulations and uses thereof | |
| CU20090062A7 (en) | USE OF ESTRADIOL VALERATE OR 17BETA-ESTRADIOL IN COMBINATION WITH DIENOGEST IN AN ORAL THERAPY TO MAINTAIN AND / OR INCREASE THE FEMALE LIBID | |
| DOP2009000079A (en) | USE OF ESTRADIOL VALERATE IN COMBINATION WITH DIENOGEST IN AN ORAL THERAPY TO MAINTAIN AND / OR INCREASE THE FEMALE LIBID |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |